Previous 10 | Next 10 |
Charles River Laboratories press release (NYSE:CRL): Q1 Non-GAAP EPS of $2.75 beats by $0.03. Revenue of $913.9M (+10.8% Y/Y) beats by $5.26M. The Company is updating its 2022 financial guidance, which was previously provided on February 16, 2022. Reported revenue growth guidance is being inc...
– First-Quarter Revenue of $913.9 Million – – First-Quarter GAAP Earnings per Share of $1.81 and Non-GAAP Earnings per Share of $2.75 – – Updates 2022 Guidance – Charles River Laboratories International, Inc. (NYSE: C...
Charles River Laboratories (NYSE:CRL) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $2.72 (+7.5% Y/Y) and the consensus Revenue Estimate is $908.64M (+10.2% Y/Y). Over the last 2 years, CRL has beaten EPS estimates 100% o...
Vancouver, Kelowna, Delta, BC - April 27, 2022 (Investorideas.com Newswire) Investorideas.com , a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advancements in artificial intelligenc...
Customized drug discovery offers integrated target-to-lead and target-to-clinic ready small molecules Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched Logica TM , an artificial intelligence (AI) powered ...
Jefferies had downgraded contract research organization Charles River Laboratories (NYSE:CRL) to hold from buy expressing concerns that there may be less spending on trials from biotech sponsors. Shares are down 8% in Monday morning trading. The firm lowered its price target to $280...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy underperformed during a pronounced rotation ...
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2022 financial results on Wednesday, May 4 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 4 th , at 9:30 a.m. ET. Investors...
Charles River Laboratories has seen continued growth. The company continues to pursue bolt-on deal-making to grow the business. Shares have been flat over the past year, albeit accompanied by some volatility in the meantime, as valuating has come down a bit. A 26 times forward...
Medpace Holdings is a healthy business trading at a discount to its intrinsic value. Price target $193-200. The company has zero debt vs peer group average of $5.6B debt. Lower risk of permanent loss of capital vs peers. Medpace top-line in the past four years grew at 17.5% CAGR v...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...